Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 9, 2012, Pages 875-885

  Schouten, J N L ^a   Van Der Ende, M E ^a   Koeter T ^a   Rossing, H H M ^a   Komuta, M ^b   Verheij, J ^c   Van Der Valk, M ^c   Hansen, B E ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DIDANOSINE; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; CASE CONTROL STUDY; CAUSE OF DEATH; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IDIOPATHIC DISEASE; IDIOPATHIC NONCIRRHOTIC PORTAL HYPERTENSION; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA;

ADENINE; ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; DIDANOSINE; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ORGANOPHOSPHONATES; RISK FACTORS; STAVUDINE; YOUNG ADULT;

EID: 84878588537     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12049     Document Type: Article

References (32)

1. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54: 1071-81.
2. Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol 2011; 54: 455-61.
3. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21: 187-92. (Pubitemid 46036926)
4. Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13: 103-7. (Pubitemid 351541679)
5. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6: 1167-9.
6. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102: 2536-40. (Pubitemid 47631766)
7. Scourfield A, Waters L, Holmes P, et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011; 22: 324-8.
8. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42: 177-82. (Pubitemid 43884712)
9. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49: 626-35.
10. Cesari M, Schiavini M, Marchetti G, et al. Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature. AIDS Patient Care STDS 2010; 24: 697-703.
11. Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009; 23: 1511-8.
12. Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009; 104: 1707-14.
13. Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24: 1171-6.
14. Cotte L, Benet T, Billioud C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. J Hepatol 2011; 54: 489-96.
15. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11: 787-97. (Pubitemid 20191384)
16. Van Sighem ASC, Gras L, Holman R, Stolte I, Prins M, De Wolf F. Monitoring report 2011. Amsterdam: The Dutch HIV monitoring foundation, 2011.
17. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54: 455-61.
18. Sciot R, Staessen D, Van Damme B, et al. Incomplete septal cirrhosis: histopathological aspects. Histopathology 1988; 13: 593-603. (Pubitemid 19038604)
19. Daly CA, Padley SP. Sonographic prediction of a normal or abnormal ERCP in suspected AIDS related sclerosing cholangitis. Clin Radiol 1996; 51: 618-21.
20. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708. (Pubitemid 30451995)
21. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165-73. (Pubitemid 35387271)
22. Walker UA, Bauerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311-7. (Pubitemid 38222171)
23. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30: 156-60. (Pubitemid 29023665)
24. Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000; 14: 273-8. (Pubitemid 30132921)
25. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001; 15: 617-20. (Pubitemid 32281357)
26. Callens S, De Schacht C, Huyst V, Colebunders R. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment. J Infect 2003; 47: 188-9. (Pubitemid 36896408)
27. Barreiro P, Jimenez-Nacher I, Garcia B, Garcia-Benayas T, Rivas P, Soriano V. Nucleoside/nucleotide backbones for the treatment of HIV infection. Curr Opin Investig Drugs 2005; 6: 812-22. (Pubitemid 41103042)
28. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000; 30: 198-200. (Pubitemid 30067084)
29. Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther 2012; 35: 1424-33.
30. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-89. (Pubitemid 40462940)
31. Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS 2011; 25: 899-904.
32. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-8. (Pubitemid 43268281)